CTX-M

CTX-M. CTX-M enzymes are a rapidly expanding and clinically critical group of extended-spectrum beta-lactamases (ESBLs) that confer bacterial resistance to a broad range of beta-lactam antibiotics, particularly later-generation cephalosporins like cefotaxime and ceftriaxone. First identified in the late 1980s, these Ambler class A enzymes are now a dominant cause of antimicrobial resistance worldwide, posing severe challenges in both hospital and community-acquired infection settings. Their genes are typically located on highly mobile plasmids, facilitating rapid dissemination across diverse Enterobacteriaceae species such as Escherichia coli and Klebsiella pneumoniae.

Overview

The discovery of the first CTX-M enzyme, initially termed CTX-M-1, was reported from a clinical isolate of Escherichia coli in Munich, Germany, in 1989. Unlike other prevalent ESBLs like TEM and SHV derivatives, which evolved from narrow-spectrum penicillinases, CTX-M enzymes appear to originate from Kluyvera species chromosomal beta-lactamases. Their rapid global spread since the 2000s is linked to the successful mobilization of their encoding genes onto conjugative plasmids and insertion sequences such as ISECp1. This has led to their establishment as a predominant ESBL type in many regions, significantly impacting the efficacy of first-line empiric therapy for serious urinary tract, bloodstream, and intra-abdominal infections.

Classification and variants

CTX-M enzymes are classified based on amino acid sequence identity into five major phylogenetic groups: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25. Each group contains numerous variants, with over 200 identified, named sequentially (e.g., CTX-M-15, CTX-M-14, CTX-M-27). The CTX-M-15 variant, belonging to the CTX-M-1 group, is particularly widespread and often associated with the successful Escherichia coli sequence type 131 (ST131) clone. Variants differ by a few key point mutations that can subtly alter their hydrolytic profile and inhibitor susceptibility. The National Center for Biotechnology Information and the Lahey Clinic maintain curated databases for tracking these genetic variants and their global distribution.

Mechanism of resistance

CTX-M enzymes function by hydrolyzing the beta-lactam ring of antibiotics, rendering them inactive. They exhibit particularly high catalytic efficiency against cefotaxime and ceftriaxone, but generally have weaker activity against ceftazidime, though some variants like CTX-M-15 have acquired enhanced ceftazidime-hydrolyzing ability through specific mutations. Resistance conferred by these enzymes is often combined with co-resistance to other antimicrobial classes like fluoroquinolones and aminoglycosides due to the carriage of additional resistance genes on the same plasmid. This multidrug resistance profile severely limits treatment options, often necessitating the use of last-resort agents such as carbapenems, which in turn drives the emergence of carbapenem-resistant Enterobacteriaceae.

Epidemiology and clinical significance

The epidemiology of CTX-M enzymes is characterized by rapid intercontinental spread. CTX-M-15 is the most globally prevalent variant, strongly associated with community-onset infections caused by Escherichia coli ST131. Other variants like CTX-M-14 are dominant in parts of Asia and Spain, while CTX-M-2 is common in South America and Japan. Major outbreaks have been documented in healthcare facilities worldwide, including in the National Health Service in the United Kingdom and the Centers for Disease Control and Prevention network in the United States. Their clinical significance is profound, as infections with CTX-M-producing Enterobacteriaceae are associated with higher rates of treatment failure, increased hospital length of stay, greater healthcare costs, and elevated mortality compared to infections caused by susceptible strains.

Detection and identification

Accurate detection in clinical laboratories is crucial for infection control and appropriate therapy. Phenotypic methods include the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommended combination disk tests and double-disk synergy test using clavulanic acid as an inhibitor. Automated systems like VITEK and BD Phoenix often incorporate ESBL detection panels. Molecular methods, considered the gold standard, involve polymerase chain reaction (PCR) for the blaCTX-M gene and DNA sequencing for variant identification. Advanced techniques like whole-genome sequencing, supported by databases from the National Center for Biotechnology Information and the Comprehensive Antibiotic Resistance Database, are increasingly used for precise epidemiological typing and tracking transmission dynamics within hospitals and the community.

Category:Enzymes Category:Antimicrobial resistance